- Conditions
- Kidney Cancer
- Interventions
- aldesleukin, recombinant interferon alfa, fluorouracil, isotretinoin, surgical procedure
- Biological · Drug · Procedure
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2002
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 1,551
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Cancer, Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Argos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Englewood, Colorado • Marietta, Georgia • Woodbury, Minnesota + 2 more
- Conditions
- Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
- Interventions
- Nivolumab, Everolimus
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 821 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 39
- States / cities
- Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 29 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Sunitinib, Temsirolimus
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Burlington, Vermont
- Conditions
- Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
- Interventions
- Pembrolizumab, Lenvatinib
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metastatic Renal Cell Cancer
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 15
- States / cities
- Springdale, Arkansas • Aurora, Colorado • Ocoee, Florida + 12 more
- Conditions
- Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2042
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
- Interventions
- chemotherapy, tipifarnib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 2
- States / cities
- San Francisco, California • Tampa, Florida
- Conditions
- Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
- Interventions
- PF-07921585, Sasanlimab
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more
- Conditions
- Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, autologous dendritic cell-adenovirus p53 vaccine, filgrastim, cyclophosphamide, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Interventions
- gemcitabine hydrochloride, cisplatin, gefitinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- SGN-2FF, pembrolizumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Biological
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Irvine, California • Miami, Florida • St Louis, Missouri + 2 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Avelumab, AVB-S6-500
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Tumors, Neoplasm Metastasis
- Interventions
- Rapamycin (sirolimus), Grapefruit Juice
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Kidney Cancer
- Interventions
- Pazopanib, Bevacizumab, Everolimus
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Kidney Cancer
- Interventions
- sunitinib malate, conventional surgery
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Kidney Cancer
- Interventions
- autologous tumor cell vaccine, keyhole limpet hemocyanin, therapeutic autologous dendritic cells, fludarabine phosphate, conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- St. Luke's Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 2
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Solid Tumors, CNS Tumors
- Interventions
- Entrectinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 15
- States / cities
- La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- etaracizumab, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Marysville, California • Sacramento, California • Ann Arbor, Michigan + 2 more
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
- Interventions
- XL092, Atezolizumab, Avelumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 40
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 33 more
- Conditions
- Cancer
- Interventions
- fluconazole, itraconazole
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Renal Cancer
- Interventions
- percutaneous cryoablation
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York